Eric Schmidt
Stock Analyst at Cantor Fitzgerald
(2.71)
# 1,821
Out of 5,172 analysts
48
Total ratings
30%
Success rate
2.53%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Eric Schmidt
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LEGN Legend Biotech | Maintains: Overweight | $75 → $74 | $17.87 | +314.10% | 3 | Dec 17, 2025 | |
| VSTM Verastem | Assumes: Overweight | n/a | $5.82 | - | 1 | Oct 16, 2025 | |
| ACLX Arcellx | Assumes: Neutral | $88 | $114.33 | -23.03% | 1 | Oct 9, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Overweight | n/a | $15.72 | - | 3 | Sep 8, 2025 | |
| SRRK Scholar Rock Holding | Initiates: Overweight | n/a | $45.50 | - | 1 | Jul 17, 2025 | |
| PRTA Prothena Corporation | Reiterates: Neutral | n/a | $8.54 | - | 2 | Jun 20, 2025 | |
| IMTX Immatics | Reiterates: Overweight | n/a | $9.69 | - | 4 | Apr 1, 2025 | |
| ALMS Alumis | Reiterates: Overweight | n/a | $25.38 | - | 4 | Mar 20, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Overweight | $13 | $18.79 | -30.76% | 2 | Mar 13, 2025 | |
| ADCT ADC Therapeutics | Reiterates: Overweight | n/a | $4.04 | - | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $46.95 | - | 4 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | n/a | $92.95 | - | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $27.92 | - | 4 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $19.32 | - | 3 | Dec 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | n/a | $30.04 | - | 2 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $292 | $183.41 | +59.21% | 3 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $370 | $458.05 | -19.22% | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.35 | - | 1 | Oct 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $2.30 | - | 1 | May 30, 2017 |
Legend Biotech
Dec 17, 2025
Maintains: Overweight
Price Target: $75 → $74
Current: $17.87
Upside: +314.10%
Verastem
Oct 16, 2025
Assumes: Overweight
Price Target: n/a
Current: $5.82
Upside: -
Arcellx
Oct 9, 2025
Assumes: Neutral
Price Target: $88
Current: $114.33
Upside: -23.03%
Summit Therapeutics
Sep 8, 2025
Reiterates: Overweight
Price Target: n/a
Current: $15.72
Upside: -
Scholar Rock Holding
Jul 17, 2025
Initiates: Overweight
Price Target: n/a
Current: $45.50
Upside: -
Prothena Corporation
Jun 20, 2025
Reiterates: Neutral
Price Target: n/a
Current: $8.54
Upside: -
Immatics
Apr 1, 2025
Reiterates: Overweight
Price Target: n/a
Current: $9.69
Upside: -
Alumis
Mar 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $25.38
Upside: -
Bicara Therapeutics
Mar 13, 2025
Reiterates: Overweight
Price Target: $13
Current: $18.79
Upside: -30.76%
ADC Therapeutics
Mar 7, 2025
Reiterates: Overweight
Price Target: n/a
Current: $4.04
Upside: -
Feb 19, 2025
Reiterates: Neutral
Price Target: n/a
Current: $46.95
Upside: -
Jan 10, 2025
Reiterates: Neutral
Price Target: n/a
Current: $92.95
Upside: -
Dec 18, 2024
Reiterates: Overweight
Price Target: n/a
Current: $27.92
Upside: -
Dec 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $19.32
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.04
Upside: -
Sep 9, 2024
Reiterates: Overweight
Price Target: $292
Current: $183.41
Upside: +59.21%
Oct 17, 2023
Reiterates: Overweight
Price Target: $370
Current: $458.05
Upside: -19.22%
Oct 17, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.35
Upside: -
May 30, 2017
Initiates: Outperform
Price Target: n/a
Current: $2.30
Upside: -